United Therapeutics: TETON Breakthrough and EPS Beat Drive Record Rally
Reading Time: 3 minutes
Clinical Milestone: The stock is shooting up on high volume after the TETON-1 study for Tyvaso in IPF has impressively achieved its primary endpoint. Market Potential: With the planned FDA application in summer 2026, the company is targeting a new billion-dollar market that could surpass previous indications in terms of revenue. Financial Strength: A massive EPS beat in the last quarter (USD 7.70 vs. USD 7.10) and a USD 2 billion share repurchase program underpin investor confidence. United Therapeutics has established...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
